Cambridge, UK, 15 February 2024 – Sareum Holdings plc (AIM: SAR), a clinical-stage biotechnology company developing next generation kinase inhibitors for autoimmune disease and cancer, today announces the completion of the single ascending
Sareum Holdings PLC (SAR.L) Subscription to raise £900,000
Subscription to raise £900,000 to progress proprietary TYK2/JAK1 programmes through final stages of preclinical development